NAMS Stock Forecast & Price Target

NewAmsterdam Pharma Co is viewed favorably because its lead asset obicetrapib has repeatedly shown meaningful LDL-C lowering, a more established lever for reducing ASCVD risk than the mechanisms that disappointed in recent CVOTs. The investment case is further supported by a sizable unmet need for an effective oral option, with management’s thesis centered on PREVAIL’s ability to deliver statistically significant MACE reductions in the ~20% range, while the company ended 3Q26 with about $643MM in cash and a net loss of $17.4MM. Beyond the core cardiovascular opportunity, regulatory progress in Europe, potential milestones of up to €817MM, and multiple follow-on readouts in 2026 and YE2027 provide several value-creating catalysts.

NewAmsterdam Pharma Co is viewed negatively because its lead asset obicetrapib still faces meaningful clinical and statistical uncertainty, with the remaining CVOT and PREVAIL interim in 1Q27 carrying a low estimated 35-38% probability of success at the interim. Even if efficacy is shown, the company must still clear FDA approval, manage safety or labeling risk, and overcome a crowded, well-capitalized competitive landscape with no approved products and uncertain payer reimbursement. Fundamentally, the stock also reflects a financing burden, as escalating R&D and commercialization costs likely require additional capital, while downside remains possible if LDL-C reductions fail to translate into durable MACE benefit.